Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor α blockade in spondylarthropathy

Arthritis and Rheumatism

Volumn 50, Issue 9, 2004, Pages 2942-2953

  Vandooren, Bernard ^a   Kruithof, Elli ^a   Yu, David T Y ^b   Rihl, Markus ^c   Gu, Jieruo ^b   De Rycke, Leen ^a   Van Den Bosch, Filip ^a   Veys, Eric M ^a   De Keyser, Filip ^a   Baeten, Dominique ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; INFLIXIMAB; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARTILAGE DEGENERATION; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DOWN REGULATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; JOINT BIOPSY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; SYNOVITIS; VASCULARIZATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DOWN-REGULATION; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; SPONDYLARTHROPATHIES; SPONDYLITIS, ANKYLOSING; SYNOVIAL FLUID; SYNOVIAL MEMBRANE; SYNOVITIS; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4444235330     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20477     Document Type: Article

References (52)

1. Arend WP, Gabay C. Cytokine networks. In: Rheumatoid arthritis: new frontiers in pathogenesis and treatment. Firestein GS, Panayi GS, Wollheim FA, editors. New York: Oxford University Press; 2000. p. 147-63.
2. Gravallese EM. Bone destruction in arthritis. Ann Rheum Dis 2002;61:84-6.
3. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827-39.
4. Gravallese EM, Darling JM, Ladd AL, Katz JN, Glimcher LH. In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium. Arthritis Rheum 1991;34:1076-84.
5. Firestein GS, Paine MM. Stromelysin and tissue inhibitor of metalloproteinases gene expression in rheumatoid arthritis synovium. Am J Pathol 1992;140:1309-14.
6. McCachren SS. Expression of metalloproteinases and metalloproteinase inhibitors in human arthritic synovium. Arthritis Rheum 1991;34:1085-93.
7. Ahrens D, Koch AE, Pope RM, Stein-Picarella M, Niedbala MJ. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum 1996;39:1576-87.
8. Clark IM, Powell LK, Ramsey S, Hazleman BL, Cawston TE. The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1993;36:372-9.
9. Walakovits LA, Moore VL, Bhardwaj N, Gallick GS, Lark MW. Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. Arthritis Rheum 1992;35:35-42.
10. Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T, Fujikawa K, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 2000;59:455-61.
11. Yoshihara Y, Obata K, Fujimoto N, Yamashita K, Hayakawa T, Shimmei M. Increased levels of stromelysin 1 and tissue inhibitor of metalloproteinases 1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 1995;38:969-75.
12. Manicourt DH, Fujimoto N, Obata K, Thonar EJ. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis: relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation. Arthritis Rheum 1995;38:1031-9.
13. Gruber BL, Sorbi D, French DL, Marchese MJ, Nuovo GJ, Kew RR, et al. Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clin Immunol Immunopathol 1996;78:161-71.
14. Nagase H, Okada Y. Proteinases and matrix degradation. In: Textbook of rheumatology. Kelley WN, Harris ED, Ruddy S, Sledge CB, editors. Philadelphia: W. B. Saunders; 1997. p. 323-41.
15. Meyer FA, Yaron I, Yaron M. Synergistic, additive, and antagonistic effects of interleukin-1β, tumor necrosis factor α, and γ-interferon on prostaglandin E, hyaluronic acid, and collagenase production of cultured synovial fibroblasts. Arthritis Rheum 1990;33:1518-25.
16. Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163-8.
17. MacNaul KL, Chartrain N, Lark M, Tocci MJ, Hutchinson NI. Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts: synergistic effects of interleukin-1 and tumor necrosis factor-α on stromelysin expression. J Biol Chem 1990;265:17238-45.
18. Zhang Y, McCluskey K, Fujii K, Wahl LM. Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-α, granulocyte-macrophage CSF, and IL-1β through prostaglandin-dependent and -independent mechanisms. J Immunol 1998;161:3071-6.
19. Cunnane G, FitzGerald O, Beeton C, Cawston TE, Bresnihan B. Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinase 1 in rheumatoid arthritis. Arthritis Rheum 2001;44:2263-74.
20. Tolboom TC, Pieterman E, van der Laan WH, Toes RE, Huidekoper AL, Nelissen RG, et al. Invasive properties of fibroblast like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3 and MMP-10. Ann Rheum Dis 2002;61:975-80.
21. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001;21:1104-17.
22. Vermaelen KY, Cataldo D, Tournoy K, Maes T, Dhulst A, Louis R, et al. Matrix metalloproteinase-9-mediated dendritic cell recruitment into the airways is a critical step in a mouse model of asthma. J Immunol 2003;171:1016-22.
23. Goldbach-Mansky R, Lee JM, Hoxworth JM, Smith D II, Duray P, Schumacher RH Jr, et al. Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis. Arthritis Res 2000;2:145-53.
24. Calin A. Radiology and spondylarthritis. Baillieres Clin Rheumatol 1996;10:455-76.
25. Baeten D, Demetter P, Cuvelier C, Van den Bosch F, Kruithof E, Van Damme N, et al. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis 2000;59:945-53.
26. Reece RJ, Canete JD, Parsons WJ, Emery P, Veale DJ. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis Rheum 1999;42:1481-4.
27. Rihl M, Baeten D, Seta N, Gu J, De Keyser F, Veys EM, et al. Technical validation of cDNA-based microarray as screening technique to identify candidate genes in synovial tissue biopsies from spondyloarthropathy patients. Ann Rheum Dis 2004;63:498-507.
28. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for classification of Spondylarthropathy. Arthritis Rheum 1991;34:1218-27.
29. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
30. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
31. Van den Bosch F, Kruithof E, Baeten D, Herssens A, De Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis a (infliximab) versus placebo in Spondylarthropathy. Arthritis Rheum 2002;46:755-65.
32. Baeten D, Van den Bosch F, Elewaut D, Stuer A, Veys EM, De Keyser F. Needle arthroscopy of the knee with synovial biopsy sampling: technical experience in 150 patients. Clin Rheumatol 1999;18:434-41.
33. Baeten D, Kruithof E, Van den Bosch F, Demetter P, Van Damme N, Cuvelier C, et al. Immunomodulatory effects of anti-tumor necrosis factor α therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001;44:186-95.
34. Baeten D, Demetter P, Cuvelier CA, Kruithof E, Van Damme N, De Vos M, et al. Macrophages expressing the scavenger receptor CD 163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol 2002;196:343-50.
35. Smeets TJ, Kraan MC, Galjaard S, Youssef PP, Smith MD, Tak PP. Analysis of the cell infiltration and expression of matrix metalloproteinases and granzyme B in paired synovial biopsy specimens from the cartilage-pannus junction in patients with RA. Ann Rheum Dis 2001;60:561-5.
36. Katrib A, Tak PP, Bertouch JV, Cuello C, McNeil HP, Smeets TJ, et al. Expression of chemokines and matrix metalloproteinases in early rheumatoid arthritis. Rheumatology 2001;40:988-94.
37. Smeets TJ, Barg EC, Kraan MC, Smith MD, Breedveld FC, Tak PP. Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis. Ann Rheum Dis 2003;62:635-8.
38. Ishiguro N, Ito T, Oguchi T, Kojima T, Iwata H, Ionescu M, et al. Relationship of matrix metalloproteinases and their inhibitors in cartilage proteoglycan and collagen turnover and inflammation as revealed by analyses of synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum 2001;44:2503-11.
39. Burbridge MF, Coge F, Galizzi JP, Boutin JA, Wets DC, Tucker GC. The role of the matrix metalloproteinases during in vitro vessel formation. Angiogenesis 2002;5:215-26.
40. Hangai M, Kitaya N, Xu J, Can CK, Kim JJ, Werb Z, et al. Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. Am J Pathol 2002;161:1429-37.
41. Galis ZS, Johnson C, Godin D, Magid R, Shipley JM, Senior RM, et al. Targeted disruption of the matrix metalloproteinase 9 gene impairs smooth muscle cell migration and geometrical arterial remodelling. Circ Res 2002;91:852-9.
42. Fraser A, Fearon U, Reece R, Emery P, Veale DJ. Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis. Arthritis Rheum 2001;44:2024-8.
43. Cunnane G, FitzGerald O, Hummel KM, Youssef PP, Gay RE, Gay S, et al. Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis. Arthritis Rheum 2001;44:1744-53.
44. Ribbens C, Martin y Porras M, Franchimont N, Kaiser MJ, Jaspar J, Damas P, et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 2002;61:161-6.
45. Omura K, Takahashi M, Omura T, Miyamoto S, Kushida K, Sano Y, et al. Changes in the concentration of plasma matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 after total joint replacement in patients with arthritis. Clin Rheumatol 2002;21:488-92.
46. Wong P, Cuello C, Bertouch JV, Roberts-Thomson PJ, Ahern MJ, Smith MD, et al. The effects of pulse methylprednisolone on matrix metalloproteinase and tissue inhibitor of metalloproteinase-1 expression in rheumatoid arthritis. Rheumatology 2000;39:1067-73.
47. Kraan MC, Reece RJ, Barg EC, Smeets TJ, Farnell J, Rosenberg R, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis: findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 2000;43:1820-30.
48. Smeets TJ, Dayer JM, Kraan MC, Versendaal J, Chicheportiche R, Breedveld FC, et al. The effects of interferon-β treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:270-4.
49. Brennan FM, Browne KA, Green PA, Jaspar JM, Maini RN, Feldman M. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-α (cA2) therapy. Br J Rheumatol 1997;36:643-50.
50. Den Broeder AA, Joosten LAB, Saxne T, Heinegard D, Fenner H, Miltenburg AMM, et al. Long term anti-tumour necrosis factor α monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 2002;61:311-8.
51. Catrina AI, Lampa J, Enestam S, Klint E, Bratt J, Klareskog L, et al. Anti-tumour necrosis factor (TNF)-α therapy (etanercept) down-regulates serum matrix metalloproteinase-3 and MMP-1 in rheumatoid arthritis. Rheumatology 2002;41:484-9.
52. Maksymowych WP, Jhangri GS, Lambert RG, Mallon C, Buenvjaie L, Perucz E, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002;29:959-65.